ArticleBMJ open2026

Value-based pricing of tislelizumab plus chemotherapy versus chemotherapy alone for advanced oesophageal squamous cell carcinoma: a Markov modelling study from the US payer perspective.

Ali A Abdeen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.